Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

TY - JOUR

T1 - Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

AU - PSO-BIO-COVID study group

AU - Talamonti, M.

AU - Galluzzo, M.

AU - Chiricozzi, A.

AU - Quaglino, P.

AU - Fabbrocini, G.

AU - Gisondi, P.

AU - Marzano, A. V.

AU - Potenza, C.

AU - Conti, A.

AU - Parodi, A.

AU - Belloni Fortina, A.

AU - Bardazzi, F.

AU - Argenziano, G.

AU - Rongioletti, F.

AU - Stingeni, L.

AU - Micali, G.

AU - Loconsole, F.

AU - Venturini, M.

AU - Bongiorno, M. R.

AU - Feliciani, C.

AU - Rubegni, P.

AU - Amerio, P.

AU - Fargnoli, M. C.

AU - Pigatto, P.

AU - Savoia, P.

AU - Nisticò, S. P.

AU - Giustini, S.

AU - Carugno, A.

AU - Cannavò, S. P.

AU - Rech, G.

AU - Prignano, F.

AU - Offidani, A.

AU - Lombardo, M.

AU - Zalaudek, I.

AU - Bianchi, L.

AU - Peris, K.

AU - Balestri, R.

AU - Bernardini, N.

AU - Botti, E.

AU - Burlando, M.

AU - Caldarola, G.

AU - Cattaneo, A.

AU - Dapavo, P.

AU - Dastoli, S.

AU - De Simone, C.

AU - Di Nuzzo, S.

AU - Diotallevi, F.

AU - Fierro, M. T.

AU - Fidanza, R.

AU - Foti, C.

N1 - Funding Information: L. Bianchi reports personal fees from speaker and as consultant for AbbVie, Novartis, Janssen‐Cilag, Pfizer, UCB and Leo Pharma, outside the submitted work. SP Cannavò has served as speaker or board member for AbbVie, Celgene, Eli Lilly, Leo Pharma, Janssen, Novartis and Sanofi Genzyme. A. Chiricozzi served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme and UCB Pharma. A. Conti served as advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Leo Pharma, Eli Lilly, Novartis, UCB Pharma, Pfizer, Sandoz, Celgene, Biogen and Janssen‐Cilag. M.C. Fargnoli has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi Genzyme, Roche, Sun Pharma and MSD. P. Gisondi has been a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, Leo pharma, Eli Lilly, Novartis, Pfizer, Sandoz and UCB. K. Peris reports personal fees for advisory board meeting from Almirall, AbbVie, Biogen, Janssen, Eli Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz and Sun Pharma outside the conduct of the work. I. Zalaudek has been a consultant and/or speaker for Novartis, Celgene and Amgen.

PY - 2020/12

Y1 - 2020/12

UR - https://www.scopus.com/pages/publications/85089190434

U2 - 10.1111/jdv.16841

DO - 10.1111/jdv.16841

M3 - Letter

SN - 0926-9959

VL - 34

SP - e770-e772

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 12

ER -